



we belong to science

# STAR CONFERENCE

Milan, March 24<sup>th</sup>-25<sup>th</sup>, 2026

## DISCLAIMER

This document has been prepared by Pharmanutra S.p.A. (the "Company") for use during meetings with investors and financial analysts and is solely for information purposes. It contains solely data and information provided by the Company or already in the public domain. This Document may not be reproduced or distributed, in whole or in part, by any person other than the Company.

This document may contain forward-looking statements about the Company based on current expectations and opinions developed by the Company, as well as based on current plans, estimates, projections and projects of the Company. These forward-looking statements are subject to significant risks and uncertainties (many of which are outside the control of Pharmanutra) which could cause a material difference between forward-looking information and actual future results. The Company does not make any guarantee that subsequent to the date of the document, there will not be any changes to the activities and/or earnings situation of the Company.

Any reference to past performance or trends or activities of the Company shall not be taken as a representation or indication that such performance, trends or activities will continue in the future.

This document does not constitute a proposal to execute a contract, an offer or invitation to purchase, subscribe or sell for any financial instrument and neither it or any part of it shall form the basis of or be relied upon in connection with any contract or commitment or investments decision whatsoever. Any decision to purchase, subscribe or sell for securities will have to be made independently of this presentation. Therefore, nothing in this presentation shall create any binding obligation or liability on the Company and its affiliates and any of their advisors or representatives.

Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any investor.


All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a comprehensive representation of the Company's cash generation performance.

All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document and are expressly qualified in their entirety by the cautionary statements included elsewhere in this document. The financial projections are preliminary and subject to change; the Company undertakes no obligation to update or revise these forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. Inevitably, some assumptions will not materialize, and unanticipated events and circumstances may affect the ultimate financial results. Projections are inherently subject to substantial and numerous uncertainties and to a wide variety of significant business, economic and competitive risks, and the assumptions underlying the projections may be inaccurate in any material respect. Therefore, the actual results achieved may vary significantly from the forecasts, and the variations may be material.


By receiving this Presentation, you acknowledge and agree to be bound by the foregoing terms, conditions, limitations and restrictions.



# PHARMANUTRA *group*



# THE EXTENSIVE PHARMANUTRA FOOTPRINT WORLDWIDE



In addition to direct subsidiaries, Pharanutra operates in **80 countries with 52 partners**, carefully selected among the best international pharmaceutical and nutraceutical companies.



## ANOTHER YEAR OF DOUBLE-DIGIT GROWTH

Net Sales Revenues:

**Foreign markets: +23.2%**  
**Domestic market: +9.2%**

**Akern: 6.8 M (+15.1%)**

**26% EBITDA margin** on net revenues.  
EBITDA margin on net revenues **excluding new business units is 31.5%** (31.4% in FY 2024).

**EPS of € 2.09** (€ 1.73 in FY 2024)

**Positive Net Financial Position** (Net cash) of **11.4 million Euro** (5.4M of net cash at 31/12/24)

Proposed Dividend of **€ 1.20 per share** (1.00 in 2024)

**+ 14%**

**NET REVENUES € 131.7 M**  
**(€ 115.4 M IN FY 2024)**

**+10%**

**EBITDA € 34.2 M**  
**(€ 31 M IN FY 2024)**



**+20%**

**€ 20 M NET RESULT**  
**(€ 16.6 M in FY 2024)**  
**15.1% ON NET REVENUES**


**+19.5 M**

**CASH GENERATED BY OPERATING ACTIVITIES**


# REMARKABLE PERFORMANCE FROM NEW BUSINESS UNITS



## REVENUE EVOLUTION: SOLID ORGANIC GROWTH OVER TIME



# POSITIVE GROWTH TREND IN PROFITABILITY



# NEW COMMERCIAL STRUCTURE TO DRIVE FURTHER GROWTH

FROM JANUARY 2026

CONSUMER HEALTH

**50** SALES REP

MEDICAL CARE

**100** SALES REP

## STRATEGIC GOALS



Directly serve  
**60%** of pharmacies



Strengthen scientific  
and market leadership



Double revenues  
within **5 years**

# NEW BUSINESS UNITS: USA BECOMING A MARKET-MAKING LEADER



## KEY RESULTS


2025 revenues: **1.5 million \$ (+664.8% vs FY2024)** with strong Q4 sales boost

Achieved **1.3% market share** and **monthly revenues for \$200K** at the end of 2025

In early March, **market share** has increased to **1.6%**

Achieved **triple digit growth on Amazon**

Ranking increased **from #333** in April 2025 to **#57** in early March 2026



Well poised for future growth:

**Product range expansion** scheduled for Q3 2026 (3 SKUs) and Q1 2027 (4 additional SKUs)

**FDA registration** and **AEO (Full) status** obtained in February 2026

# NEW BUSINESS UNITS: CHINA

## FULL DIGITAL DISTRIBUTION APPROACH AND HIGH GROWTH POTENTIAL

Strong presence on **5 online platforms:**



### KEY RESULTS

2025 revenues: **3.26 million € (+ 74.1% vs FY2024)**

In December 2025, **SiderAL Folico ranked #1 on the JDG store** in the New Arrivals List for imported mineral health supplements.

In March 2026, **SiderAL's** ranking has been stable at **#2 on TMG** in the Iron supplements **category**, with peaks as **#1** in some days.

In Q1 2025, expansion of product offer with the launch of 3 **Apportal® SKUs**.



**Growth potential:** the online Chinese supplement market size is around **13.5 billion €**.  
Pharmanutra has a **client basis** of almost **60,000 unique buyers** with **30% repeat customers**.

# SCIENTIFIC INNOVATION: FUELING THE GROWTH OF TOMORROW

## PRODUCT PIPELINE

In the following fields:

- New **iron formulations** for US market
- **Multivitamins** and micro-elements
- **Elderly** and **children**
- **Athletes'** performance
- **Obesity, bariatric surgery, sarcopenia**

## RESEARCH PIPELINE

130 prototypes in pre-clinical evaluation in the following fields:

- **Bone fracture** and **metabolism**
- **Brain function** integrity
- **Gastric** protection
- **Intestinal** inflammation
- Future **iron upgrade**





PHARMANUTRA  
*group*